FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079777659> ?p ?o ?g. }

• W2079777659 endingPage "379" @default.
• W2079777659 startingPage "369" @default.
• W2079777659 abstract "3-Aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) is a novel small molecule inhibitor of ribonucleotide reductase (RR) with clinical signs of activity in pancreatic cancer. Therefore, the Phase 2 Consortium (P2C) initiated a trial (two single stage studies with planned interim analysis) of 3-AP at 96 mg/m(2) intravenously days 1-4 and 15-18 of a 28-day cycle in both chemotherapy-naive and gemcitabine-refractory (GR) patients with advanced pancreatic cancer. The primary endpoint was survival at six months (chemotherapy-naive) and four months (GR). Secondary endpoints were toxicity, response, overall survival, time to progression and mechanistic studies. Fifteen patients were enrolled including one chemotherapy-naïve and 14 GR. The chemotherapy-naïve patient progressed during cycle 1 with grade 3 and 4 toxicities. Of 14 GR patients, seven received two cycles, six received one cycle and one received eight cycles. Progression precluded further treatment in 11 GR patients. Additionally, one died of an ileus in cycle 1 considered related to treatment and two stopped treatment due to toxicity. Five GR patients had grade 4 toxicities possibly related to 3-AP and six GR patients had grade 3 fatigue. Toxicities and lack of meaningful clinical benefit prompted early study closure. Four-month survival in GR patients was 21% (95% CI: 8-58%). Correlative studies confirmed that 3-AP increased the percentage of S-phase buccal mucosal cells, the presence of multidrug resistance gene polymorphisms appeared to predict leukopenia, and baseline pancreatic tumor RR M2 expression was low relative to other tumors treated with 3-AP. In conclusion, this regimen appears inactive against predominantly GR pancreatic cancer. RR M2 protein may not have a critical role in the malignant potential of pancreatic cancer." @default.
• W2079777659 created "2016-06-24" @default.
• W2079777659 creator A5004280495 @default.
• W2079777659 creator A5014356411 @default.
• W2079777659 creator A5015092618 @default.
• W2079777659 creator A5016348831 @default.
• W2079777659 creator A5017792432 @default.
• W2079777659 creator A5022511085 @default.
• W2079777659 creator A5029890317 @default.
• W2079777659 creator A5033720986 @default.
• W2079777659 creator A5056823515 @default.
• W2079777659 creator A5091511322 @default.
• W2079777659 date "2008-02-16" @default.
• W2079777659 modified "2023-09-25" @default.
• W2079777659 title "A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas" @default.
• W2079777659 cites W1535189264 @default.
• W2079777659 cites W1931508686 @default.
• W2079777659 cites W1946785805 @default.
• W2079777659 cites W1965734230 @default.
• W2079777659 cites W1966040155 @default.
• W2079777659 cites W1984896504 @default.
• W2079777659 cites W1989790390 @default.
• W2079777659 cites W1991823030 @default.
• W2079777659 cites W1996222967 @default.
• W2079777659 cites W2003185404 @default.
• W2079777659 cites W2006277511 @default.
• W2079777659 cites W2009615948 @default.
• W2079777659 cites W2022470615 @default.
• W2079777659 cites W2025399633 @default.
• W2079777659 cites W2051644638 @default.
• W2079777659 cites W2056183436 @default.
• W2079777659 cites W2077500782 @default.
• W2079777659 cites W2083315452 @default.
• W2079777659 cites W2084590133 @default.
• W2079777659 cites W2097642908 @default.
• W2079777659 cites W2118226539 @default.
• W2079777659 cites W2118342649 @default.
• W2079777659 cites W2119391569 @default.
• W2079777659 cites W2123344367 @default.
• W2079777659 cites W2135352785 @default.
• W2079777659 cites W2139248078 @default.
• W2079777659 cites W2148434078 @default.
• W2079777659 cites W2150391295 @default.
• W2079777659 cites W2154574630 @default.
• W2079777659 cites W2158134441 @default.
• W2079777659 cites W2163636362 @default.
• W2079777659 cites W2164121851 @default.
• W2079777659 cites W3011562054 @default.
• W2079777659 cites W3041047318 @default.
• W2079777659 cites W4232195096 @default.
• W2079777659 cites W4297819854 @default.
• W2079777659 doi "https://doi.org/10.1007/s10637-008-9123-6" @default.
• W2079777659 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4461052" @default.
• W2079777659 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18278438" @default.
• W2079777659 hasPublicationYear "2008" @default.
• W2079777659 type Work @default.
• W2079777659 sameAs 2079777659 @default.
• W2079777659 citedByCount "71" @default.
• W2079777659 countsByYear W20797776592012 @default.
• W2079777659 countsByYear W20797776592013 @default.
• W2079777659 countsByYear W20797776592014 @default.
• W2079777659 countsByYear W20797776592015 @default.
• W2079777659 countsByYear W20797776592016 @default.
• W2079777659 countsByYear W20797776592017 @default.
• W2079777659 countsByYear W20797776592018 @default.
• W2079777659 countsByYear W20797776592019 @default.
• W2079777659 countsByYear W20797776592020 @default.
• W2079777659 countsByYear W20797776592021 @default.
• W2079777659 countsByYear W20797776592022 @default.
• W2079777659 countsByYear W20797776592023 @default.
• W2079777659 crossrefType "journal-article" @default.
• W2079777659 hasAuthorship W2079777659A5004280495 @default.
• W2079777659 hasAuthorship W2079777659A5014356411 @default.
• W2079777659 hasAuthorship W2079777659A5015092618 @default.
• W2079777659 hasAuthorship W2079777659A5016348831 @default.
• W2079777659 hasAuthorship W2079777659A5017792432 @default.
• W2079777659 hasAuthorship W2079777659A5022511085 @default.
• W2079777659 hasAuthorship W2079777659A5029890317 @default.
• W2079777659 hasAuthorship W2079777659A5033720986 @default.
• W2079777659 hasAuthorship W2079777659A5056823515 @default.
• W2079777659 hasAuthorship W2079777659A5091511322 @default.
• W2079777659 hasBestOaLocation W20797776592 @default.
• W2079777659 hasConcept C104292427 @default.
• W2079777659 hasConcept C104317684 @default.
• W2079777659 hasConcept C121608353 @default.
• W2079777659 hasConcept C126322002 @default.
• W2079777659 hasConcept C141071460 @default.
• W2079777659 hasConcept C143998085 @default.
• W2079777659 hasConcept C185592680 @default.
• W2079777659 hasConcept C203092338 @default.
• W2079777659 hasConcept C2776694085 @default.
• W2079777659 hasConcept C2780210213 @default.
• W2079777659 hasConcept C2780258809 @default.
• W2079777659 hasConcept C2780580376 @default.
• W2079777659 hasConcept C2780873365 @default.
• W2079777659 hasConcept C29730261 @default.
• W2079777659 hasConcept C4710235 @default.
• W2079777659 hasConcept C535046627 @default.

• next